Clinical Trials Logo

Retinal Drusen clinical trials

View clinical trials related to Retinal Drusen.

Filter by:
  • None
  • Page 1

NCT ID: NCT05056025 Recruiting - AMD Clinical Trials

Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.

REVERS
Start date: December 2, 2020
Phase: N/A
Study type: Interventional

A pilot study to establish the efficacy and safety of supplementation with postbiotics in patients with macular degeneration.

NCT ID: NCT03946085 Completed - Clinical trials for Age-related Macular Degeneration

Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)

AMD
Start date: January 19, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the clinical benefits in visual function from dietary supplementation of the Lumega-Z carotenoid liquid-supplement in participants with drusen and at risk of AMD. The effects of Lumega-Z supplementation will be compared to an active comparator, the AREDS2 multivitamin.

NCT ID: NCT03478878 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation

Start date: May 14, 2018
Phase: Early Phase 1
Study type: Interventional

Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for they eye to adjust to low light. This is known as dark adaptation. This is particularly significant in people with reticular pseudodrusen (RPD). Identifying and watching the early to middle stages of AMD and changes in dark adaptation might help researchers learn to stop the disease before it becomes severe. Taking vitamin A might help improve vision in people with RPD. Objectives: To see if taking 16,000 IU of vitamin A per day improves vision in people with RPD. Also to improve understanding of RPD and associated dark adaptation. Eligibility: Adults ages 50 and older with RPD and normal liver function Design: Participants will be screened with: Medical and eye disease history Eye exam: The pupil will be dilated with eye drops. Pictures will be taken of the retina and the inside of the eye. Including the screening visit, participants will have at least 5 visits. They will be about once a month over 6 months and last 4-6 hours. Visits include: Questions about eye problems in certain light Eye exam Blood and urine tests Dark adaptation protocol: Participants will sit at a machine in a dark room. They will look into the machine and push a button when they see a light. This lasts 20-40 minutes. Participants will take a vitamin A supplement by mouth once a day for 2 months. They will record when they take the pills in a diary.

NCT ID: NCT02960828 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study

SAVE
Start date: January 2016
Phase: N/A
Study type: Interventional

This study aims to validate the efficacy and safety of subthreshold laser photocoagulation on high-risk macular drusen in early age-related macular degeneration which has a high risk of conversion to exudative AMD.

NCT ID: NCT02800356 Completed - Clinical trials for Age-Related Macular Degeneration

Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD

Start date: June 2016
Phase: N/A
Study type: Interventional

To evaluate the effectiveness of subthreshold laser treatment on retinal sensitivity in patients with reticular pseudodrusen and incipient Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Secondary objective is to investigate changes in best-corrected visual acuity, atrophy progression and safety.

NCT ID: NCT02569892 Completed - Clinical trials for Macular Degeneration

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen. The goal of the study is to determine if this treatment will reduce macular drusen volume and also whether this might improve visual acuity or reduce the risk of conversion to advanced age-related macular degeneration defined as development of choroidal neovascularization or geographic atrophy.

NCT ID: NCT01666821 Completed - Geographic Atrophy Clinical Trials

A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population

Start date: May 2004
Phase: N/A
Study type: Observational

To investigate pathomorphological and functional variations of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a Chinese population using optical coherence tomography (OCT) to find which kinds of Fundus characteristics indicated exudative AMD.